首页> 外文期刊>International Journal of Radiation Oncology, Biology, Physics >Usefulness of intraluminal brachytherapy combined with external beam radiation therapy for submucosal esophageal cancer: long-term follow-up results.
【24h】

Usefulness of intraluminal brachytherapy combined with external beam radiation therapy for submucosal esophageal cancer: long-term follow-up results.

机译:腔内近距离放射疗法与外部束放射疗法联合治疗黏膜下食管癌的有效性:长期随访结果。

获取原文
获取原文并翻译 | 示例
           

摘要

PURPOSE: To assess the efficacy of radiation therapy (RT) by using intraluminal brachytherapy (IBT) combined with external beam RT (EBRT) for submucosal esophageal cancer. METHODS AND MATERIALS: Between 1991 and 2005, 59 consecutive patients received definitive RT without chemotherapy. IBT was performed after patients completed EBRT as a booster therapy for 17 patients, using low-dose-rate Cs-137 sources until 1997, and for 19 patients, using high-dose-rate Ir-192 sources thereafter. The long-term outcomes were investigated with a median follow-up time of 61 months. RESULTS: Logoregional recurrences and distant metastases were observed in 14 patients and in 2 patients in the lung, respectively, and 5 patients were rescued by salvage treatments. The 5-year logoregional control and cause-specific survival rates were 75% and 76%, respectively. The 5-year cause-specific survival rate in the EBRT group was 62%, whereas the corresponding rate in the IBT group was 86% (p = 0.04). Multivariate analysis revealed that IBT was the most powerful predictor of survival but did not reach a significant level (p = 0.07). There were five esophageal ulcers in the IBT group, but no ulcers developed with small fractions of 3 Gy. Grade 2 or higher cardiorespiratory complications developed in 2 patients (5.6%) in the IBT group and in 3 patients (13.0%) in the EBRT group. CONCLUSIONS: Combining IBT with EBRT is suggested to be one of the preferable treatment modalities for medically inoperable submucosal esophageal cancer because of its preferable local control and survival probabilities, with appreciably less morbidity.
机译:目的:通过腔内近距离放射治疗(IBT)结合外照射RT(EBRT)评估食管黏膜下食管癌的放射治疗(RT)疗效。方法和材料:1991年至2005年间,连续59例患者接受了未经化疗的明确RT。在患者完成EBRT的增强治疗后,对IBT进行了治疗,其中有17例患者使用低剂量率Cs-137来源,直到1997年,其余19例患者使用高剂量率的Ir-192来源,之后进行。对长期结果进行了调查,中位随访时间为61个月。结果:分别在14例和2例肺部患者中观察到徽标区域复发和远处转移,并通过抢救治疗挽救了5例患者。 5年徽标区域控制率和特定原因生存率分别为75%和76%。 EBRT组的5年特定病因存活率为62%,而IBT组的相应比率为86%(p = 0.04)。多变量分析显示,IBT是存活率的最有力预测指标,但未达到显着水平(p = 0.07)。 IBT组有5例食道溃疡,但小剂量的3 Gy均未发生溃疡。 IBT组有2名患者(5.6%)发生了2级或更高级别的心肺并发症,而EBRT组则有3名患者(13.0%)发生了2级或更高级别的心肺并发症。结论:IBT与EBRT联合使用被认为是可手术治疗的医学上不能手术的粘膜下食管癌的一种优选治疗方式,因为它具有较好的局部控制和生存率,且发病率明显较低。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号